Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Globulin for Hypo- or Agammaglobulinemia
NCT00161993Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2002
- Primary completion
- Sep 2003
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of immune globulin intravenous (human) in primary immunodeficiency disease (PID), agammaglobulinemia and hypogammaglobulinemia, sponsored by Takeda. Primary endpoint: Trough levels of total immunoglobulin G (IgG). Started Jun 2002; status: completed.
02
Drugs
immune globulin intravenous (human)
03
Conditions
primary immunodeficiency disease (PID)agammaglobulinemiahypogammaglobulinemia
Beyond the preview
Go deeper on NCT00161993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161993.